Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM) - PubMed
4 hours ago
- #furmonertinib
- #leptomeningeal metastases
- #EGFR-mutant NSCLC
- Furmonertinib-based triplet therapy (including antiangiogenic therapy and chemotherapy) significantly improves overall survival (OS) in patients with EGFR-mutant NSCLC and leptomeningeal metastases (LM) compared to mono or dual regimens.
- In a large-scale retrospective study of 618 patients, triplet therapy achieved a median OS of 17.91 months, with benefits maintained even in those with prior third-generation EGFR-TKI exposure or poor performance status.
- Furmonertinib dosing at 80 mg/day or 160 mg/day was associated with longer OS than 240 mg/day, and the regimen showed a clinical response rate of 66.7% with manageable treatment-related adverse events.